Literature DB >> 2157754

Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations.

H R Brunner1, J Ménard, B Waeber, M Burnier, J Biollaz, J Nussberger, M Bellet.   

Abstract

For the general practitioner to be able to prescribe optimal therapy to his individual hypertensive patients, he needs accurate information on the therapeutic agents he is going to administer and practical treatment strategies. The information on drugs and drug combinations has to be applicable to the treatment of individual patients and not just patient study groups. A basic requirement is knowledge of the dose-response relationship for each compound in order to choose the optimal therapeutic dose. Contrary to general assumption, this key information is difficult to obtain and often not available to the physician for many years after marketing of a drug. As a consequence, excessive doses are often used. Furthermore, the physician needs comparative data on the various antihypertensive drugs that are applicable to the treatment of individual patients. In order to minimize potential side effects due to unnecessary combinations of compounds, the strategy of sequential monotherapy is proposed, with the goal of treating as many patients as possible with monotherapy at optimal doses. More drug trials of a crossover design and more individualized analyses of the results are badly needed to provide the physician with information that he can use in his daily practice. In this time of continuous intensive development of new antihypertensive agents, much could be gained in enhanced efficacy and reduced incidence of side effects by taking a closer look at the drugs already available and using them more appropriately in individual patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157754     DOI: 10.1097/00004872-199001000-00002

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  17 in total

Review 1.  Progress in the 1980s and new directions in the 1990s with hypertension management. From the stepped-care approach to the individualised programme in hypertension treatment and control.

Authors:  H Pardell; P Armario; R Hernández
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 2.  Selective versus nonselective beta adrenoceptor antagonists in hypertension.

Authors:  L M Van Bortel; A J Ament
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 3.  Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy?

Authors:  D A Sica
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

Review 4.  Antihypertensive Combination Treatment: State of the Art.

Authors:  M Burnier
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

Review 5.  Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.

Authors:  Domenic A Sica
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  The place of diuretics in the treatment of hypertension: a historical review of classical experience over 30 years.

Authors:  A G Dupont
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

Review 7.  Low dose loop diuretics in essential hypertension. Experience with torasemide.

Authors:  I Achhammer; P Metz
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 8.  Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection.

Authors:  Bernard Waeber; François Feihl; Luis M Ruilope
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists.

Authors:  G Gleerup; B Persson; T Hedner; K Winther
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 10.  Fixed low-dose combination therapy for hypertension.

Authors:  Bernard Waeber
Journal:  Curr Hypertens Rep       Date:  2002-08       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.